Skip to main content
Device Global Header

Subscribe
or Renew

Advanced Search

This article is available to subscribers. Subscribe now. Already have an account? Sign in

PerspectiveFree Preview

Time to Reevaluate U.S. Mifepristone Restrictions

List of authors.
  • Jane E. Henney, M.D.,
  • and Helene D. Gayle, M.D., M.P.H.

After nearly two decades of use, research, and a comprehensive review, all of which clearly demonstrate that mifepristone is extremely safe and effective, the distribution restrictions imposed by the FDA at the time of approval may no longer be appropriate.

Continue reading this article

Select an option below:

Create your account to get 2 free subscriber-only articles each month.

Get Free Access Now Subscribe For Full Access

Already have an account?

Sign In

Print subscriber?

Activate your online access.

Funding and Disclosures

Disclosure forms provided by the authors are available at NEJM.org.

This article was published on June 26, 2019, at NEJM.org.

Author Affiliations

From the National Academy of Medicine, Washington, DC (J.E.H.); and the Chicago Community Trust, Chicago (H.D.G.).

Print Subscriber? Activate your online access.